PMID- 33126409
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Oct 28
TI  - Roles of Non-Coding RNAs on Anaplastic Thyroid Carcinomas.
LID - 10.3390/cancers12113159 [doi]
LID - 3159
AB  - Anaplastic thyroid cancer (ATC) remains as one of the most aggressive human 
      carcinomas with poor survival rates in patients with the cancer despite 
      therapeutic interventions. Novel targeted and personalized therapies could solve 
      the puzzle of poor survival rates of patients with ATC. In this review, we 
      discuss the role of non-coding RNAs in the regulation of gene expression in ATC 
      as well as how the changes in their expression could potentially reshape the 
      characteristics of ATCs. A broad range of miRNA, such as miR-205, miR-19a, 
      miR-17-3p and miR-17-5p, miR-618, miR-20a, miR-155, etc., have abnormal 
      expressions in ATC tissues and cells when compared to those of non-neoplastic 
      thyroid tissues and cells. Moreover, lncRNAs, such as H19, Human leukocyte 
      antigen (HLA) complex P5 (HCP5), Urothelial carcinoma-associated 1 (UCA1), 
      Nuclear paraspeckle assembly transcript 1 (NEAT1), etc., participate in 
      transcription and post-transcriptional regulation of gene expression in ATC 
      cells. Dysregulations of these non-coding RNAs were associated with development 
      and progression of ATC by modulating the functions of oncogenes during tumour 
      progression. Thus, restoration of the abnormal expression of these miRNAs and 
      lncRNAs may serve as promising ways to treat the patients with ATC. In addition, 
      siRNA mediated inhibition of several oncogenes may act as a potential option 
      against ATC. Thus, non-coding RNAs can be useful as prognostic biomarkers and 
      potential therapeutic targets for the better management of patients with ATC.
FAU - Das, Plabon Kumar
AU  - Das PK
AD  - Department of Biochemistry and Molecular Biology, University of Rajshahi, 
      Rajshahi 6205, Bangladesh.
FAU - Asha, Saharia Yeasmin
AU  - Asha SY
AD  - Department of Biochemistry and Molecular Biology, University of Rajshahi, 
      Rajshahi 6205, Bangladesh.
FAU - Abe, Ichiro
AU  - Abe I
AD  - School of Medicine, Griffith University, Gold Coast, QLD 4222, Australia.
AD  - Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi 
      Hospital, Chikushino, Fukuoka 818-8502, Japan.
FAU - Islam, Farhadul
AU  - Islam F
AUID- ORCID: 0000-0001-5262-4702
AD  - Department of Biochemistry and Molecular Biology, University of Rajshahi, 
      Rajshahi 6205, Bangladesh.
AD  - Institute for Glycomics, Griffith University, Gold Coast Campus, Gold Coast, QLD 
      4222, Australia.
FAU - Lam, Alfred K
AU  - Lam AK
AUID- ORCID: 0000-0003-2771-564X
AD  - School of Medicine, Griffith University, Gold Coast, QLD 4222, Australia.
LA  - eng
GR  - NA/Griffith University/
PT  - Journal Article
PT  - Review
DEP - 20201028
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7693255
OTO - NOTNLM
OT  - Anaplastic thyroid carcinoma
OT  - lncRNAs
OT  - miRNAs
OT  - non-coding RNAs
OT  - siRNAs
OT  - targeted therapy
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
PMCR- 2020/10/28
CRDT- 2020/10/31 01:01
PHST- 2020/09/28 00:00 [received]
PHST- 2020/10/23 00:00 [revised]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
PHST- 2020/10/28 00:00 [pmc-release]
AID - cancers12113159 [pii]
AID - cancers-12-03159 [pii]
AID - 10.3390/cancers12113159 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Oct 28;12(11):3159. doi: 10.3390/cancers12113159.